<DOC>
	<DOCNO>NCT02169752</DOCNO>
	<brief_summary>This research study look use drug ambrisentan improve right ventricle function people systemic sclerosis-associated pre-pulmonary arterial hypertension . It also look use right ventricle function change marker disease severity .</brief_summary>
	<brief_title>Ambrisentan Improvement Right Ventricular Strain Scleroderma Associated Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>This research study look use drug ambrisentan improve right ventricle function people systemic sclerosis-associated pre-pulmonary arterial hypertension . It also look use right ventricle function change marker disease severity . Pre-pulmonary arterial hypertension borderline elevation blood pressure lung . Pre-pulmonary arterial hypertension currently treat drug therapy use pulmonary arterial hypertension . It represent group patient risk develop pulmonary arterial hypertension . The administration ambrisentan experimental part study . Ambrisentan approve FDA use improve right ventricle function people pre-pulmonary arterial hypertension . You still receive normal clinical care . The purpose study learn ambrisentan role treat systemic sclerosis-associated pre-pulmonary arterial hypertension . Ambrisentan already approve use people systemic sclerosis-associated pulmonary arterial hypertension , study want research role people pre-pulmonary arterial hypertension .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Age &gt; 18 year , &lt; 80 year Systemic sclerosis follow feature : 1 . Duration Raynaud 's phenomenon &gt; 8 year 2 . Anticentromere antibody positivity 3. isolated nucleolarpattern ANA positivity 4 . Extensive telangiectasias 5 . DLCO &lt; 60 % absence extensive ILD 6 . FVC % /DLCO % &gt; 1.6 7 . Unexplained dyspnea Right heart catheterizationproven pre PAH ( mean PAP 2025 mmHg pulmonary capillary wedge pressure &lt; 15 mmHg ) Systolic blood pressure &gt; 100 mmHg Reliable contraception woman childbearing age Informed consent &lt; 18 year &gt; 80 year Left ventricular ejection fraction &lt; 55 % Systolic diastolic leave ventricular congestive heart failure Liver disease ( abnormal AST/ALT , chronic hepatitis , cirrhosis ) Extensive ILD FVC &lt; 60 % Pregnant Breastfeeding woman Cyclosporine use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Pre-Pulmonary Atrial Hypertension</keyword>
</DOC>